semaglutide dulaglutide Dosing Patterns of and in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study | Advances in Therapy Semaglutide Shows Comparable Glycemic Control

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

Discover how GLP-1 receptor targeting is reshaping metabolic disease treatment

Learn about how this medication may affect fertility and getting pregnant on Ozempic.

Skyrizi became another giant in the broader pathway story

Considering switching from Semaglutide to Tirzepatide

Strive is a triple-accredited 503A compounding pharmacy offering semaglutide and tirzepatide nationwide through major telehealth partners.